• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Parexel Shares Jump 17% After the Bell on Profit Forecast

Parexel Shares Jump 17% After the Bell on Profit Forecast

April 27, 2009
CenterWatch Staff

Parexel International, a global contract research organization (CRO), reported an 8% increase in service revenue for its third quarter, flat quarterly profits, but raised its profit outlook for 2009. The CRO’s shares jumped 17.7% in after hours trading to $9.51 a share after closing Monday at $8.08.

The Waltham, Mass., company recorded service revenue of $264.5 million for the third quarter ended March 31, up from $245.3 million a year ago. Excluding the negative impact of foreign exchange and the net positive impact of acquisitions and divestitures of $17 million from the third quarter of fiscal year 2009, and $900,000 in divestitures from the third quarter of fiscal year 2008, revenue grew 15.8% year-over-year.

Parexel recorded flat net income of $14.2 million, or 25 cents a share for the quarter. The CRO increased its 2009 profit forecast to 97 cents to 99 cents per share, up from 94 cents to 98 cents.

“The company’s positive quarterly results were a clear reflection of the determined focus by our employees to control costs and achieve both our financial and operational targets," stated Josef H. von Rickenbach, Parexel’s Chairman and CEO. "I am proud of our staff’s ability to grow service revenue and expand operating margins in today’s challenging environment. In addition, we were able to generate a very respectable level of new business wins in the quarter, despite some market headwinds.”

Parexel’s backlog was $2.04 billion at the end of the March quarter, an increase of 6.8% year-over-year.  The reported backlog included gross new business wins of $427.3 million, cancellations of $95.8 million and a negative impact from foreign exchange rates of $37.4 million. Other CROs have been hurt recently by large cancellations.

“I remain confident regarding Parexel’s prospects for the future, and believe that our global footprint, and a diverse service offering have positioned us well for the current environment. Revenue growth has been quite healthy, especially on a same-store, constant currency basis. The steps that we have taken over the past year to better leverage our global presence in managing our own costs have been paying off,” von Rickenbach said.

For fiscal year 2009, consolidated service revenue is expected to be in the range of $1.075 to $1.080 billion, down from previous guidance of $1.095 to $1.115 billion.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing